-

07:16:11 PM

TXMD Stock News

TXMD - TherapeuticsMD Inc

01/03/23 6:50 AM

Nasdaq : TXMD

low float

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

TherapeuticsMD, Inc., an innovative, leading women’ s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited, an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, pursuant to which TXMD granted Mayne Pharma an exclusive...

RHEA-AI

very positive

12/04/22 6:00 PM

Nasdaq : TXMD

low float

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

TherapeuticsMD, Inc., an innovative, leading women’ s healthcare company, today announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited, an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United...

RHEA-AI

positive

11/14/22 4:05 PM

Nasdaq : TXMD

earningslow float

TherapeuticsMD Announces Third Quarter 2022 Financial Results

TherapeuticsMD, Inc., an innovative, leading women’ s healthcare company, today reported financial results for the third quarter ended September 30, 2022. While our third quarter 2022 net revenues declined $4.5 million compared with the prior year, through disciplined cost control measures, we were able to reduce our operating expenses by $22 million...

RHEA-AI

neutral

10/31/22 6:50 AM

Nasdaq : TXMD

low float

TherapeuticsMD Announces Additional $7 Million Private Placement

TherapeuticsMD, Inc., an innovative, leading women’ s healthcare company, announced today that it received an additional $7 million private investment in the Company’ s Series A Preferred Stock from Rubric Capital Management LP. TherapeuticsMD expects to use the proceeds from the transaction for working capital. To learn more about TherapeuticsMD, please...

RHEA-AI

neutral

10/03/22 6:50 AM

Nasdaq : TXMD

low float

TherapeuticsMD Announces $7 Million Private Placement

TherapeuticsMD, Inc., an innovative, leading women’ s healthcare company, announced today that it received a $7 million private investment in the Company’ s Series A Preferred Stock from Rubric Capital Management LP. TherapeuticsMD expects to use the proceeds from the transaction for working capital. To learn more about TherapeuticsMD, please visit...

RHEA-AI

neutral

09/12/22 6:50 AM

Nasdaq : TXMD

managementlow float

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

TherapeuticsMD, Inc., an innovative, leading women’ s healthcare company, announced today the appointment of Dr. Dr. Bernick and Mr. Glickman succeed Mr. Prior to this appointment, Dr. Bernick, the Company’ s co-founder, served as Chief Scientific and Medical Officer, and Mr. Glickman served as Chief Business Officer.

RHEA-AI

very positive

08/15/22 6:50 AM

Nasdaq : TXMD

earningslow float

TherapeuticsMD Announces Second Quarter 2022 Financial Results

TherapeuticsMD, Inc., an innovative, leading women’ s healthcare company, today reported financial results for the Second Quarter ended June 30, 2022. We were also able to repay $120 million dollars of debt with the proceeds of our successful divestiture of our vitaCare unit,” said Hugh O’ Dowd, CEO of TherapeuticsMD. BIJUVA net product revenue of $2.7 million for...

RHEA-AI

neutral

08/08/22 6:50 AM

Nasdaq : TXMD

conferencesearningslow float

TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

TherapeuticsMD, Inc., an innovative, leading women’ s healthcare company, today announced that it will report its second quarter 2022 financial results on Monday, August 15, 2022, at 8:30 a.m. ET prior the opening of the U.S. financial markets. A live webcast and audio archive for the event may be accessed on the home page or from the“ Investors& Media” section of the...

RHEA-AI

neutral

08/01/22 6:50 AM

Nasdaq : TXMD

low float

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

TherapeuticsMD, Inc., an innovative, leading women’ s healthcare company, announced today that it has received a $15 million private investment in the Company’ s common stock and a new series of preferred stock from Rubric Capital Management LP. TherapeuticsMD expects to use the proceeds from the transaction to fulfill its near-term operating capital...

RHEA-AI

very positive

07/13/22 6:50 AM

Nasdaq : TXMD

low float

TherapeuticsMD Announces Expiration of Tender Offer

TherapeuticsMD, Inc., an innovative, leading women’ s healthcare company, announced today that Athene Merger, Inc., an affiliate of EW Healthcare Partners, did not acquire the required majority of shares of TXMD through the previously announced tender offer by the extended offer deadline of one minute after 11:59 PM Eastern Time on July 12, 2022.

RHEA-AI

neutral

1 2 3 4 5 6 Next

TXMD Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.therapeuticsmd.com
CeoRobert Finizio
Security nameTherapeuticsMD Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees416
Tags
- Health Technology
- Pharmaceuticals: Generic
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address951 W Yamato Rd Ste 220
StateFlorida
CityBoca Raton
Zip33431-4440
CountryUnited States
Phone15619611900

About TherapeuticsMD Inc

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues.